NASDAQ · Biotechnology

Akari Therapeutics, Plc (AKTX) Stock

$8.43 -0.35% NASDAQ: AKTX Healthcare

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.

Valuation

MetricValue
Price$8.43
Market Cap$9.65M
P/E Ratio-0.01
P/B Ratio0.01
P/S Ratio0.00
EPS (TTM)$-20800.00
52-Week High$49.60
52-Week Low$3.02
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-123.29%
ROA-82.76%
ROCE-144.12%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.05
Current Ratio0.27

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-17.0M$-23.0M$-17.0M$-22.0M$-17.0M
Net Profit$-17.0M$-18.0M$-10.0M$-20.0M$-17.0M
EPS$-649600.00$-455200.00$-163200.00$-132800.00$-20800.00
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$12.0M$14.0M$4.0M$51.0M$48.0M
Total Liabilities$6.0M$12.0M$5.0M$28.0M$20.0M
Cash$9.0M$13.0M$4.0M$3.0M$5.0M
Borrowings$0$0$0$3.0M$1.0M

Latest News

European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading MT Newswires · Jul 27, 2026 European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading MT Newswires · Jul 24, 2026 European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT Newswires · Jul 22, 2026 Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity GlobeNewswire · Jul 22, 2026 European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading MT Newswires · Jul 21, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-19.0M$-22.0M$-16.0M$-13.0M$-11.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-5.0M$4.0M$-9.0M$-1.0M$3.0M
Free Cash Flow$-19.0M$-22.0M$-16.0M$-13.0M$-11.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.26
FCF Yield-112.80%
Quick Ratio0.27
Interest Coverage-30.92
Return 1Y-81.35%
Return 3Y-95.17%
Return 5Y-99.37%

Ownership

Insiders Held16.80%
Institutions Held8.98%
Institutions Float Held10.79%
Institutional HolderSharesReport Date
Armistice Capital, LLC38,9222026-03-31
Cresset Asset Management, LLC20,5612026-03-31
Skyview Financial Group LLC5142025-12-31
IFP Advisors, Inc1812026-06-30
Truvestments Capital, LLC12026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Akari Therapeutics, Plc

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

Akari Therapeutics, Plc is headquartered in US.

Akari Therapeutics, Plc (AKTX) stock trades at $8.43 with a market capitalization of $9.65M. The stock is valued at a price-to-earnings (P/E) ratio of -0.01, price-to-book of 0.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.02 and $49.60, and currently trades 83.0% below its 52-week high.

On profitability, Akari Therapeutics, Plc generates a return on equity (ROE) of -123.29%, return on capital employed of -144.12%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.akaritx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides